Robust Q1 and FDA Approval for da Vinci 5 Fail to Reverse Intuitive Surgical’s Slide

Intuitive Surgical posted a 23% jump in first-quarter revenue to $2.77 billion and secured a key FDA green light for its da Vinci 5 system in cardiology, yet its stock continues to languish near 52-week lows. The shares touched €356.55 on Monday – the deepest trough in a year – and have shed 22.71% since the start of 2026. The selling pressure has hit the surgical robotics specialist harder than many of its medtech peers, even as the company’s operational metrics flash unequivocal strength.

Underlying demand for robotic-assisted surgery shows no sign of slowing. Global procedure volume rose 17% year over year in the first quarter, and Intuitive Surgical placed 232 of its new da Vinci 5 systems. The platform recently received FDA approval for specific cardiac procedures, and management secured a CE mark for the European market. Those approvals have prompted the company to raise its annual procedure growth forecast to as high as 16%. Recurring revenue from instruments and accessories continues to provide a steady tailwind, and the net margin of 28.15% remains more than double that of rival Stryker’s 13.20%.

Much of the stock’s weakness stems from a broad sector rotation that has disproportionately punished high-multiple names. Edwards Lifesciences and other medtech peers have also suffered, but Intuitive Surgical’s shares now trade well below their 50-day moving average of roughly €401. The 200-day line sits more than 13% above the current price, leaving a formidable gap before any technical recovery can take hold.

Should investors sell immediately? Or is it worth buying Intuitive Surgical?

Valuation compression has been severe. The trailing P/E multiple currently ranges between 39.71 and 52.48, depending on the earnings metric used – down from a five-year median of approximately 70.28. While the stock is no longer priced at the extremes seen in earlier years, it still commands a premium that reflects the company’s quality and recurring revenue model. Analysts expect 2026 earnings per share of $10.40, representing growth of 15.2% from the prior year.

The professional investment community remains largely constructive despite the drawdown. Of the 26 analysts tracked, 18 rate the shares a buy, and Zacks assigns the stock a rank 2 “Buy” recommendation. The average price target is roughly $582, with some analysts setting year-end targets near $586 – implying potential upside of more than 30% from current levels.

Looking ahead, the second-quarter report due in July 2026 will provide fresh data on da Vinci 5 placements and procedure volumes. Management is also scheduled to present detailed strategy updates at investor events this summer. Sustained procedure growth and further regulatory wins could help close the gap between fundamental performance and market sentiment. A shortfall in placements or a renewed rotation away from growth stocks, however, would leave the shares vulnerable near the recent lows. For now, the stock’s trajectory hinges on whether operational momentum can eventually outweigh the sector-wide forces that have driven it to the sidelines.

Ad

Intuitive Surgical Stock: New Analysis - 14 May

Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Intuitive Surgical analysis...

en | US46120E6023 | ROBUST | boerse | 69329043 |